title: Management of castration-resistant (advanced) prostate cancer (CRPC): rationale, progress and future directions.
abstract: BACKGROUND
  Prostate cancer is the most common solid organ cancer and the second most common cause of cancer-related deaths in Australian men.
  
  
  OBJECTIVE
  The aim of our review is to provide general practitioners with up-to-date information about castration resistance and hormonal dependence in prostate cancer. We summarise the current ongoing and completed clinical trials targeting hormonal pathways in metastatic prostate cancer.
  
  
  CONCLUSIONS
  The treatment paradigm of metastatic castration-resistant prostate cancer has changed markedly in the past decade and new agents targeting androgen receptor pathways have been introduced. However, the biggest challenge for clinicians is to develop guidelines to integrate these agents into clinical practice.
authors.affiliation: MBBS, MRCS (Edin), MS, Urology Advanced Trainee, Prince of Wales Hospital, Sydney, Port Macquarie, NSW.
authors.forename: Sam
authors.initials: S
authors.lastname: Chopra
authors.forename: Prem
authors.initials: P
authors.lastname: Rashid
mesh_terms: D059002:Androgen Receptor Antagonists / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001315:Australia; D018450:Disease Progression; D000077143:Docetaxel; D058006:General Practice; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009919:Orchiectomy; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000473:pathology*; D011868:Radioisotopes / Q000627:therapeutic use; D011883:Radium / Q000627:therapeutic use; D043823:Taxoids / Q000627:therapeutic use
chemical_list: D059002:Androgen Receptor Antagonists; D000970:Antineoplastic Agents; D011868:Radioisotopes; D043823:Taxoids; D000077143:Docetaxel; C581106:radium Ra 223 dichloride; D011883:Radium